These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 36594101)

  • 1. Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.
    Tan H; Yue T; Chen Z; Wu W; Xu S; Weng J
    Int J Biol Sci; 2023; 19(1):66-88. PubMed ID: 36594101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor 21 - a key player in cardiovascular disorders?
    Lenart-Lipińska M; Duma D; Hałabiś M; Dziedzic M; Solski J
    Horm Mol Biol Clin Investig; 2016 Jun; 30(2):. PubMed ID: 27305706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fibroblast growth factor 21 plays a protective role in cardiovascular diseases by inducing autophagy].
    Li YK; He SY; Wang C; Shi YC; Liu JH
    Sheng Li Xue Bao; 2022 Aug; 74(4):633-638. PubMed ID: 35993214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21.
    Domouzoglou EM; Naka KK; Vlahos AP; Papafaklis MI; Michalis LK; Tsatsoulis A; Maratos-Flier E
    Am J Physiol Heart Circ Physiol; 2015 Sep; 309(6):H1029-38. PubMed ID: 26232236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity.
    Babaknejad N; Nayeri H; Hemmati R; Bahrami S; Esmaillzadeh A
    Horm Metab Res; 2018 Jun; 50(6):441-452. PubMed ID: 29883971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    BioDrugs; 2008; 22(1):37-44. PubMed ID: 18215089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of FGF21 in the pathogenesis of cardiovascular disease.
    Zhang Y; Liu D; Long XX; Fang QC; Jia WP; Li HT
    Chin Med J (Engl); 2021 Dec; 134(24):2931-2943. PubMed ID: 34939977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of FGF21 in atherosclerosis pathogenesis.
    Tabari FS; Karimian A; Parsian H; Rameshknia V; Mahmoodpour A; Majidinia M; Maniati M; Yousefi B
    Rev Endocr Metab Disord; 2019 Mar; 20(1):103-114. PubMed ID: 30879171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis.
    Lakhani I; Gong M; Wong WT; Bazoukis G; Lampropoulos K; Wong SH; Wu WKK; Wong MCS; Ong KL; Liu T; Tse G;
    Metabolism; 2018 Jun; 83():11-17. PubMed ID: 29410351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of fibroblast growth factor 21 in atherosclerosis.
    Kokkinos J; Tang S; Rye KA; Ong KL
    Atherosclerosis; 2017 Feb; 257():259-265. PubMed ID: 28012645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target.
    Zhao M; Zheng Z; Li C; Wan J; Wang M
    Front Immunol; 2022; 13():1053175. PubMed ID: 36518760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.
    Woo YC; Xu A; Wang Y; Lam KS
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):489-96. PubMed ID: 23134073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of FGF21 on glycemic control.
    Strowski MZ
    Horm Mol Biol Clin Investig; 2017 Jun; 30(2):. PubMed ID: 28593912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.
    Geng L; Lam KSL; Xu A
    Nat Rev Endocrinol; 2020 Nov; 16(11):654-667. PubMed ID: 32764725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases.
    Zhao L; Niu J; Lin H; Zhao J; Liu Y; Song Z; Xiang C; Wang X; Yang Y; Li X; Mohammadi M; Huang Z
    EBioMedicine; 2019 Oct; 48():462-477. PubMed ID: 31631034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus.
    So WY; Leung PS
    Med Res Rev; 2016 Jul; 36(4):672-704. PubMed ID: 27031294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolvin D2 and its receptor GPR18 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target.
    Zhao M; Zheng Z; Yin Z; Zhang J; Qin J; Wan J; Wang M
    Pharmacol Res; 2023 Sep; 195():106832. PubMed ID: 37364787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs.
    Kim KH; Lee MS
    J Endocrinol; 2015 Jul; 226(1):R1-16. PubMed ID: 26116622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.